2017
DOI: 10.1016/j.brachy.2017.04.048
|View full text |Cite
|
Sign up to set email alerts
|

Long Term Outcomes of I 125 Eye Plaque Brachytherapy in Patients with Choroidal Melanoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
2
0

Year Published

2017
2017
2017
2017

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…The group's institutional experience found that patients treated with I 125 eye plaque brachytherapy had similar local control and metastases rates and had better visual preservation in comparison to those outcomes reported by Collaborative Ocular Melanoma Studies (3). And finally, in the fourth award recipient's presentation investigators discussed that the incomplete PET/CT response rate in cervical cancer patients was documented in 17% of centrally reviewed patients following MRI based brachytherapy for cervical cancer (4).…”
mentioning
confidence: 91%
See 1 more Smart Citation
“…The group's institutional experience found that patients treated with I 125 eye plaque brachytherapy had similar local control and metastases rates and had better visual preservation in comparison to those outcomes reported by Collaborative Ocular Melanoma Studies (3). And finally, in the fourth award recipient's presentation investigators discussed that the incomplete PET/CT response rate in cervical cancer patients was documented in 17% of centrally reviewed patients following MRI based brachytherapy for cervical cancer (4).…”
mentioning
confidence: 91%
“…The third award recipient, Sparks et al, presented their findings regarding long-term outcomes for patients with choroidal melanoma treated with I 125 eye plaque brachytherapy (3). The group's institutional experience found that patients treated with I 125 eye plaque brachytherapy had similar local control and metastases rates and had better visual preservation in comparison to those outcomes reported by Collaborative Ocular Melanoma Studies (3).…”
mentioning
confidence: 99%